More patients help drug firms pass 'valley of death'

August 11, 2014
Back to TopCommentsE-mailPrintBookmark and Share

There’s no question the pharmaceutical industry has boatloads of cash.

Global sales of prescription drugs total nearly $1 trillion annually, according to IMS Health, a Connecticut-based market research firm.

Drug companies spend about $200 billion per year on researching and developing new drugs, according to life sciences investment firm Burrill & Co.

On top of that, venture capitalists last year plowed $4.5 billion into U.S. drug discovery firms, according to a MoneyTree report from Thomson Reuters and the National Venture Capital Association.

So when industry consultants and analysts a few years ago predicted patient advocacy groups would become critical sources of development funding, I was skeptical.

But patient groups—especially those formed around rare and untreatable diseases—are indeed playing a crucial role in getting experimental drugs across the proverbial “valley of death”—where none of those deep-pocketed players want to put their money.

That’s how it worked for Indianapolis-based Chondrial Therapeutics LLC, as I wrote about in this past weekend’s IBJ. Co-founders Dr. Mark Payne and Steve Plump, who used to be chief marketing officer at Indianapolis-based drug giant Eli Lilly and Co., had pitched their drug to large pharma and biotechnology firms.

Payne got two years of funding from Shire Pharmaceuticals, but when the company looked for another round to run a clinical trial, it came up empty handed.

So it turned to a patient organization, Friedreich’s Ataxia Research Alliance. One board member has now put $1.1 million into Chondrial to help it prepare for its first human trial in 2016.

Patients, along with their families and committed advocates, are turning out to be better sources of funding because they tolerate risk better than drug companies and investors. For patients—particularly those suffering from a disease with no treatment, as is the case with Friedreich’s ataxia—the risk of losing their money is, of course, a much smaller risk than losing their life.

Drug companies, while they may not be spending much money at these early stages, are more active than ever in talking to patient advocacy groups about developments in their disease.

Ron Bartek, who co-founded Friedreich’s Ataxia Research Alliance with his wife after their son was diagnosed with the rare genetic disorder at age 11, told me the interest of major drug companies has soared since the mid-2000s. He noted that Pfizer Inc. sent a team of employees to Bartek’s for an entire day to get the lay off the land on Friedreich’s ataxia.

The research alliance has built up a clinical database of more than 2,200 patients, which is critical for getting drug researchers started. It has also raised $30 million to fund research into cures for the disease.

"I know of no other more passionate pursuit than a parent’s pursuit of their child’s health," Bartek said.

That passion also translates into a willingness to pay high prices for drugs that give hope where none existed. Companies such as Novartis and Genzyme (now part of Sanofi) have gotten rich by launching disease-altering treatments for ailments that were once incurable. As patients live longer, the drugs can rack up huge sales.

“The research economics become very different if it truly has an impact on long life,” said Dr. Tim Franson, chief medical officer of Indianapolis-based life sciences consulting firm YourEncore, which maintains a network for 8,000 former pharmaceutical professionals.

Patients are also good sources of funding for a reason beyond money. Active patient groups like Friedreich’s Ataxia Research Alliance can help drug companies find the patients they need in a hurry.

Only one in every 50,000 people suffer from Friedreich’s ataxia, so finding a patient and then finding a doctor to conduct a clinical trial with him or her can be hugely expensive and time-consuming.

But patient groups have typically already done the hard work of attracting the relevant patients. When Bartek helped Edison Pharmaceuticals find patients for its latest Phase 2 trial of its drug for Friedreich’s ataxia, it took only two hours and 43 minutes.

Most drug companies take weeks, at least, to find the patients they need.

In addition, patient groups can actually help set the standard for success in a drug trial. The Wall Street Journal reported last week that a group for patients suffering from Duchenne muscular dystrophy—a rare form of an already rare disease—worked with the U.S. Food and Drug Administration to change the “primary endpoint” an experimental drug will be expected to meet to receive market approval.

Parent Project Muscular Dystrophy, a group focused on Duchenne muscular dystrophy, worked with 80 scientists, clinicians and drug professionals to write draft guidance for pharmaceutical companies trying to develop drugs to treat the fatal condition. The guidance calls for different measures of success than the typical six-minute walking test so that younger patients and those already seriously disabled by the disease could participate in the drug trials.

Franson was on the team that helped write that guidance for FDA, which still must approve it. But he’s encouraged by FDA’s willingness to be flexible.

“We’re certainly hopeful that this Duchenne example is replicated, in rare diseases but even outside of it,” Franson said. “I give them a lot of credit for stepping out and trying to establish new models for rare diseases. I’m very optimistic for how this will impact in other diseases.”

ADVERTISEMENT
  • nice approach in developing new medicine
    It is a nice strategy to approach parents or patients families for research. I really hope there will be a good progress especially in duchenne muscular dystrophy research.

Post a comment to this blog

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT
  1. What became of this project? Anyone know?

  2. Scott, could you post an enlarged photo of the exterior of the building? This will be a great addition to Walnut Street. This area will only continue to develop with additions like this. Also, please give us more updates on the "Cultural Trail light" expansion. Also a great move for the city, as long as there is maintenance money set aside.

  3. Great story IBJ! Citizens don't have a real sense of the financial magnitude of supporting Indy's sports and tourism sector. The CIB was a brilliant idea for creating a highly integrated public-private partnership to support this sector from the economic activity it generates. Unfortunately, most folks think the benefits of that economic activity accrue directly to the City budget, and it doesn't. So though the CIB is facing lean times (covering its costs while maintaining minimally acceptable reserves), the City is operating with deficit - less tax revenue than expenses each year - with a very fragile reserve balance. That's why it's so challenging for the City to fund basic needs or new intitatives (e.g. pre-k education; new jail), and some credit rating agencies have downgraded Indy from it's past stellar AAA status. More reporting on City finances would be welcomed.

  4. Sure, I'll admit that it bugs me to see that the IBJ.COM censors it's blog posts almost as much as the D of I does when someone points out the falsehoods and fabrications. _____But I think it bothers me almost as much that Captain/Defender/Disciple get his yanked too. You see, those of us with a sense of integrity, humanity, compassion, and a need for fact based opinion WANT to see all of his screeds posted. It makes our point so much better than we can do it ourselves.

  5. We're conflating two very different topics. Voter fraud is a myth and excessive gun violence is all too real. I just hope rational gunowners decide to stop being shouted down by the, well, let's call them "less rational" ones.

ADVERTISEMENT